BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28
• 31

• 

  Employer Resources

  Employers’ Markets Don’t Last, Companies Should Focus on Purpose-Driven Culture

  While the job market is tough for life sciences professionals right now, it won’t always be. Employers must continue striving to create fulfilling work environments, as the market won’t always be in their favor, say biopharma execs.

  March 10, 2025

   · 

  4 min read

   · 

  Chantal Dresner
• 

  Obesity

  GLP-1 Side Effects Only One Factor Driving Patient Discontinuation Rates

  While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that myriad variables are causing patients to stop treatment.

  March 10, 2025

   · 

  5 min read

   · 

  Kate Goodwin
• 

  COVID-19

  Novavax Applies Lessons Learned From Turbulent COVID-19 Experience

  As sales of its COVID vaccine plummet, Novavax is looking ahead toward other novel vaccines, brought to market with the help of the company’s pharma partners—something it opted not to do as the pandemic swept the globe in 2020.

  March 10, 2025

   · 

  6 min read

   · 

  Heather McKenzie
• 

  Immunology and inflammation

  BMS’ Sotyktu Notches Phase III Win in Psoriatic Arthritis

  In the plaque psoriasis arena, Sotyktu is facing off against Amgen’s Otezla and is facing the threat of upcoming competition from Alumis’ investigational TYK2 inhibitor.

  March 10, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Cardiovascular disease

  Mineralys’ Hypertension Drug Drops Blood Pressure in Phase II/III, Setting Up Market Clash

  Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in a pair of clinical trials.

  March 10, 2025

   · 

  2 min read

   · 

  Dan Samorodnitsky
• 

  Opinion

  FDA Faces Challenging Decision on Biomarker-Based Label Restrictions

  The FDA’s Oncologic Drugs Advisory Committee recently voted to narrow the label for checkpoint inhibitors Keytruda and Opdivo in stomach and esophageal cancers based on PD-L1 expression levels—but the high unmet need in these patient populations should also be considered.

  March 10, 2025

   · 

  5 min read

   · 

  Harpreet Singh
• 

  Regulatory

  FDA Action Alert: GSK, Alnylam, Sanofi and More

  On the agenda for the FDA this month are two RNA-based treatments for rare diseases.

  March 10, 2025

   · 

  7 min read

   · 

  Tristan Manalac
• 

  Immunology and inflammation

  Amgen, Kyowa Kirin’s Rocatinlimab Picks Up Steam With Late-Stage Atopic Dermatitis Win

  In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the antibody’s efficacy in that study to be underwhelming.

  March 10, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Immunology and inflammation

  J&J’s Oral IL-23R Blocker Sets New Standard in Plaque Psoriasis, Beating BMS’ Sotyktu

  Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing skin and easing symptom severity in patients with plaque psoriasis.

  March 10, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Weight loss

  Novo Dips After CagriSema’s Latest Lower-Than-Expected Weight Loss Readout

  The latest data showed 15.7% weight loss in patients with diabetes after 68 weeks. In December 2024, CagriSema returned another disappointing readout for Novo, eliciting weight-loss of 22.7% in patients without diabetes, below the pharma’s prior projection of 25%.

  March 10, 2025

   · 

  2 min read

   · 

  Tristan Manalac